Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07581860 · ClinicalTrials.gov registry record
Growth Hormone Resistance of Beta-cells
A clinical trial, sponsored by University of Missouri-Columbia.
- Not yet
- Registry status
- 10
- Enrollment target
NCT07581860: Clinical Trial study, sponsored by University of Missouri-Columbia.
NCT07581860 is a clinical trial that has not yet begun recruiting, run by University of Missouri-Columbia. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07581860 has not yet begun recruiting, sponsored by University of Missouri-Columbia.
- NOT YET RECRUITING
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.
Primary Outcome
Insulin secretion rate in relationship to plasma glucose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-09-01 |
What is known before NCT07581860 opens enrollment
NCT07581860 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07581860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07581860 about?
NCT07581860 is a clinical study titled "Growth Hormone Resistance of Beta-cells". The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to a...
What is the current status of trial NCT07581860?
This trial is currently not yet recruiting. The enrollment target is 10 participants. The study started on 2026-08-01. Estimated completion is 2030-09-01.
Who is sponsoring clinical trial NCT07581860?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI